Provista Diagnostics to Present at the 2015 Canaccord Genuity Medical Technology & Diagnostics Forum

New York, NY, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a corporate overview at the upcoming Canaccord Genuity Medical Technology & Diagnostics Forum taking place November 19, 2015 at the Westin Grand Hotel in New York, NY.

Dr. Reese will be presenting at 1:20 p.m. Eastern Standard Time. 

About Provista Diagnostics, Inc.

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at

Information about Provista Diagnostics' clinical trials is available at

About Canaccord Genuity Medical Technology & Diagnostics Forum

Canaccord Genuity Medical Technology & Diagnostics Forum is a one-day event that profiles over 90 public and private Med-Tech and Diagnostic companies in Cardiovascular, Diabetes, ENT, Wound Care, Women's Healthcare, Ophthalmology, Aesthetics, Obesity, Robotics & Imaging, and Medical Diagnostics, Personalized Medicine, Next Generation Sequencing and Point of Care Diagnostics. It is comprised of Fireside chat presentations for public companies, company presentations for private companies and one to one meetings with company management teams.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC.  These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT: David R. Holmes 
         Provista Diagnostics, Inc. 
         (212) 202-3170